Article Text

Download PDFPDF
Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial
  1. K F Damji,
  2. A M Bovell,
  3. W G Hodge,
  4. W Rock,
  5. K Shah,
  6. R Buhrmann,
  7. Y I Pan
  1. University of Ottawa Eye Institute, Ottawa, Ontario, Canada
  1. Correspondence to: K F Damji University of Ottawa Eye Institute, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6; kdamji{at}


Aims: To compare selective laser trabeculoplasty (SLT) and argon laser trabeculoplasty (ALT), in terms of intraocular pressure (IOP) lowering, in patients with open-angle glaucoma.

Methods: 176 eyes of 152 patients were enrolled in this study, 89 in the SLT and 87 in the ALT groups. Patients were randomised to receive either SLT or ALT treatment to 180° of the trabecular meshwork. Patients were followed up to 12 months after treatment. The main outcome measured was IOP lowering at 12 months after treatment, compared between the SLT and ALT groups.

Results: No significant difference (p = 0.846) was found in mean decrease in IOP between the SLT (5.86 mm Hg) and ALT (6.04 mm Hg) groups at 1 year or at any other time points, nor were there any significant differences in the rate of early or late complications between the two groups.

Conclusions: SLT is equivalent to ALT in terms of IOP lowering at 1 year, and is a safe and effective procedure for patients with open-angle glaucoma.

  • ALT, argon laser trabeculoplasty
  • IOP, intraocular pressure
  • OAG, open-angle glaucoma
  • PXG, pseudoexfoliation glaucoma
  • SLT, selective laser trabeculoplasty

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Published Online First 9 August 2006

  • Funding: Lumenis provided financial support for this study.

  • Competing interests: The authors have no proprietary interest in the Selecta 7000 laser or in Lumenis